Literature DB >> 29058471

Assessment of the validity of the CUDIT-R in a subpopulation of cannabis users.

Mallory Loflin1, Kimberly Babson2, Kendall Browne3, Marcel Bonn-Miller4.   

Abstract

BACKGROUND: The Cannabis Use Disorders Identification Test-Revised (CUDIT-R) is an 8-item measure used to screen for cannabis use disorders (CUD). Despite widespread use of the tool, assessments of the CUDIT-R's validity in subpopulations are limited.
OBJECTIVES: The current study tested the structural validity and internal consistency of one of the most widely used screening measures for CUD (i.e., CUDIT-R) among a sample of military veterans who use cannabis for medicinal purposes.
METHODS: The present study used confirmatory factor analysis (CFA) to test the internal consistency and validity of the single-factor structure of the original screener among a sample of veterans who use cannabis for medicinal purposes (n = 90 [90% male]; Mage = 55.31, SD = 15.37). Measures included demographics and the CUDIT-R, obtained from the baseline assessment of an ongoing longitudinal study.
RESULTS: The CFA revealed that the single-factor model previously validated in recreational using samples only accounted for 38.34% of total variance in responses on the CUDIT-R (χ2 = 66.09, df = 28, p < 0.05; RMSEA = 0.06) and demonstrated acceptable but modest internal consistency (Cronbach's α = 0.73).
CONCLUSION: More psychometric work is needed to determine the reliability and validity of using the CUDIT-R to screen for CUD among military veterans who use medicinal cannabis and other subpopulations of cannabis users.

Entities:  

Keywords:  CUDIT-R; cannabis use disorders; medicinal cannabis; veterans

Mesh:

Year:  2017        PMID: 29058471     DOI: 10.1080/00952990.2017.1376677

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  7 in total

Review 1.  The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.

Authors:  Mallory J E Loflin; Brian D Kiluk; Marilyn A Huestis; Will M Aklin; Alan J Budney; Kathleen M Carroll; Deepak Cyril D'Souza; Robert H Dworkin; Kevin M Gray; Deborah S Hasin; Dustin C Lee; Bernard Le Foll; Frances R Levin; Joshua A Lile; Barbara J Mason; Aimee L McRae-Clark; Ivan Montoya; Erica N Peters; Tatiana Ramey; Dennis C Turk; Ryan Vandrey; Roger D Weiss; Eric C Strain
Journal:  Drug Alcohol Depend       Date:  2020-04-26       Impact factor: 4.492

2.  A longitudinal examination of daily patterns of cannabis and alcohol co-use among medicinal and recreational veteran cannabis users.

Authors:  Rachel Gunn; Kristina Jackson; Brian Borsari; Jane Metrik
Journal:  Drug Alcohol Depend       Date:  2019-10-23       Impact factor: 4.492

3.  Evidence Base Update for Brief, Free, and Accessible Youth Mental Health Measures.

Authors:  Emily M Becker-Haimes; Alexandra R Tabachnick; Briana S Last; Rebecca E Stewart; Anisa Hasan-Granier; Rinad S Beidas
Journal:  J Clin Child Adolesc Psychol       Date:  2019-12-11

4.  A quadripartite model of passion for marijuana use: Associations with consumption, consequences, craving, and satisfaction with life.

Authors:  Sean Dolan; Brooke Arterberry; Alan Davis
Journal:  Addict Res Theory       Date:  2020-01-31

Review 5.  Cannabis based medicines and cannabis dependence: A critical review of issues and evidence.

Authors:  Anne K Schlag; Chandni Hindocha; Rayyan Zafar; David J Nutt; H Valerie Curran
Journal:  J Psychopharmacol       Date:  2021-02-17       Impact factor: 4.153

6.  Development of a Cannabis Assessment Tool (CAT-1) to measure current and lifetime marijuana use among older Veterans.

Authors:  Salomeh Keyhani; Ann Abraham; Beth Cohen; Marzieh Vali; Sodahm Robin Yoo; Camille Dollinger; Stacey Steigerwald
Journal:  BMJ Open       Date:  2020-01-14       Impact factor: 2.692

7.  Controlled administration of cannabis to mitigate cannabis-attributable harm among recreational users: a quasi-experimental study in Germany.

Authors:  Jakob Manthey; Jens Kalke; Jürgen Rehm; Moritz Rosenkranz; Uwe Verthein
Journal:  F1000Res       Date:  2020-03-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.